Last reviewed · How we verify
Transparent Adhesive Dressing
Transparent Adhesive Dressing is a Small molecule drug developed by Solventum US LLC. It is currently in Phase 2 development. Also known as: TAD, Polyurethane Dressing, Transparent Membrane Dressing.
Transparent Adhesive Dressing is used to treat various conditions, including non-melanoma skin cancer, superficial cutaneous lesions, dislodged catheter, pressure ulcers, and chronic full-thickness skin wounds. It is applied as a simple adhesive dressing, often compared to pressure dressing in clinical studies.
-
Baseline phase 2 → approval rate
+15.3pp
Industry-wide phase 2 drugs reach approval ~15.3% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas).
| Regulator | Country | Likely year | Lag vs FDA |
|---|---|---|---|
| FDA | US | 2031–2034 | — |
| EMA | EU | 2032–2035 | +0.7 yr |
| MHRA | GB | 2032–2035 | +0.7 yr |
| Health Canada | CA | 2032–2036 | +0.9 yr |
| TGA | AU | 2032–2036 | +1.2 yr |
| PMDA | JP | 2032–2036 | +1.5 yr |
| NMPA | CN | 2033–2037 | +2.3 yr |
| MFDS | KR | 2032–2036 | +1.4 yr |
| CDSCO | IN | 2032–2037 | +1.8 yr |
| ANVISA | BR | 2033–2037 | +2.3 yr |
Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).
Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.
At a glance
| Generic name | Transparent Adhesive Dressing |
|---|---|
| Also known as | TAD, Polyurethane Dressing, Transparent Membrane Dressing |
| Sponsor | Solventum US LLC |
| Modality | Small molecule |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- Effect of Central Venous Catheter Dressing Types on Device-Related Pressure Injuries (NA)
- Peripheral Catheter Pressure Ulcer Prevention in Pediatry : Use of Compresses Versus Standard Care (NA)
- Compare Stoma Reversal Wound Outcomes Between NPWT and Secondary Intention Healing (NA)
- Impact of ECMO Cannula Chlorhexidine-impregnated Dressings to Decrease Extracorporeal Membrane Oxygenation-cannula Related Infection Rate (NA)
- Experimental Infection of Hookworm-naïve Adults With Dermally-applied Infectious Necator Americanus Hookworm Larvae (PHASE1)
- Efficacy of a Photosynthetic Dermal Matrix for the Treatment of Full-Thickness Skin Wounds (PHASE2)
- Impact of Cyanoacrylate Glue on PICC Line Dressing Care (NA)
- The Effect of Three Different Nasogastric Tube Fixation Materials on Pressure Injury (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Transparent Adhesive Dressing CI brief — competitive landscape report
- Transparent Adhesive Dressing updates RSS · CI watch RSS
- Solventum US LLC portfolio CI
Frequently asked questions about Transparent Adhesive Dressing
What is Transparent Adhesive Dressing?
Who makes Transparent Adhesive Dressing?
Is Transparent Adhesive Dressing also known as anything else?
What development phase is Transparent Adhesive Dressing in?
Related
- Manufacturer: Solventum US LLC — full pipeline
- Also known as: TAD, Polyurethane Dressing, Transparent Membrane Dressing
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing